C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
16 mars 2022 16h05 HE
|
C4 Therapeutics, Inc.
– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and...
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
09 mars 2022 08h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
08 mars 2022 16h30 HE
|
C4 Therapeutics, Inc.
- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a...
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
24 févr. 2022 07h00 HE
|
C4 Therapeutics, Inc.
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting – –...
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
10 janv. 2022 07h00 HE
|
C4 Therapeutics, Inc.
– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022– – IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial...
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
C4 Therapeutics Added to NASDAQ Biotechnology Index
17 déc. 2021 08h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
10 nov. 2021 16h01 HE
|
C4 Therapeutics, Inc.
– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting – – Investigational New...
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
11 août 2021 16h02 HE
|
C4 Therapeutics, Inc.
– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 – – Received Orphan Drug Designation for CFT7455 for the...
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma
11 août 2021 16h01 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that...